動物用医薬品原薬製造の世界市場

動物用医薬品原薬製造の世界市場は2030年までに125億米ドルに達する見込み

2024年に87億米ドルと推定される動物用医薬品原薬製造の世界市場は、2024年から2030年にかけてCAGR 6.3%で成長し、2030年には125億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるインハウスサービスは、CAGR 7.1%を記録し、分析期間終了時には93億米ドルに達すると予測されます。契約型アウトソーシングサービスセグメントの成長率は、分析期間中CAGR 4.0%と推定されます。

米国市場は24億米ドル、中国はCAGR 10.0％で成長すると予測

米国の動物用医薬品原薬製造市場は、2024年に24億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに26億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と6.2％と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の動物用医薬品原薬製造市場- 主要動向と促進要因のまとめ

動物用医薬品原薬製造が動物用医薬品のサプライチェーンの中心である理由

動物用医薬品原薬（API）は、動物用医薬品の調合に使用される中核的な生物学的活性物質です。これらのAPIは、家畜、コンパニオンアニマル、水生種の疾病予防、治療、性能強化に使用される医薬品の基礎となります。動物用医薬品原薬の製造は、抗生物質、抗寄生虫薬、抗炎症薬、ワクチンなど幅広い製品をサポートしています。製造プロセスには、動物用原薬の規制品質基準を満たす合成、発酵、精製、製剤化が含まれます。

動物用原薬の製造は、特定の薬局方ガイドラインと適正製造規範（GMP）を遵守する必要があり、さらに汚染防止と動物種固有の有効性に重点を置かなければならないです。動物の健康が食品の安全性、公衆衛生、経済的生産性と密接に結びついているため、安全で一貫した原薬の供給は動物用ヘルスケアシステムの継続に不可欠です。このため、特に家禽、豚、牛の各セグメントで使用される大量生産の家畜用医薬品については、サプライチェーンの弾力性への注目が高まっています。

規制の変化と世界貿易はAPI製造にどのような影響を与えているか？

動物用医薬品原薬の製造は、残留薬物規制、抗菌剤スチュワードシップ、輸出品質コンプライアンスに焦点を当てた進化する規制の枠組みによって形成されています。現在、多くの地域で動物用医薬品の原産地と組成のトレーサビリティと透明性のある文書化が要求されています。このため、原薬メーカーに対する監視の目が厳しくなり、FDA、EMA、各国の獣医当局が発行するような動物用医薬品GMP基準に準拠した製造施設に対する需要が高まっています。

動物用原薬の国際取引は、VICHガイドラインやコーデックス規格のようなハーモナイゼーション・イニシアチブにも影響されます。これらは動物由来食品中の動物用医薬品の残留モニタリングプログラム及び一日摂取許容量に影響を及ぼします。製造業者は、地域によって異なる動物用原薬の承認経路をナビゲートしなければならず、多くの場合、輸出先ごとにカスタマイズされた製造と文書化が必要となります。このようなコンプライアンス要件により、大手および中堅のAPI製造業者は、認証の拡大、監査準備の改善、地域特有の規制に関する専門知識への投資を促しています。

製造戦略においてプロセス技術とアウトソーシングモデルはどのような役割を果たすか？

合成、発酵、下流工程技術の進歩により、純度、収率、製造コストの管理がより一層可能になっています。スループットを向上させ、コンタミネーションリスクを軽減するために、連続処理システムやモジュール生産システムの採用が進んでいます。微生物や酵素による合成法は、動物用ホルモンやビタミン原薬に適用されている一方、抗寄生虫剤のような複雑な分子は、高度に制御された化学合成ワークフローを必要としています。

製造受託機関（CMO）や開発・製造受託機関（CDMO）は動物用医薬品原薬のサプライチェーンでより大きな役割を果たしています。多くの動物用医薬品会社は、動物用原料に特化した専門の第三者製造業者にAPI製造を委託しています。このモデルは拡張性、コスト最適化、規制遵守をサポートする一方で、医薬品開発者は製剤化と流通に集中することができます。動物用医薬品のパイプラインが生物学的製剤に多様化するにつれ、生物学的製剤の能力を持つCMOは有効成分開発において不可欠なパートナーになりつつあります。

動物用医薬品原薬製造の世界的成長を支える要因とは？

動物用医薬品原薬製造市場の成長は、動物性タンパク質に対する需要の高まり、コンパニオンアニマルケアの増加、疾病管理プロトコルの厳格化に関連するいくつかの要因によってもたらされます。商業的畜産と水産養殖の拡大が、抗寄生虫薬、抗生物質、栄養原薬の大量需要を牽引しています。先進地域と新興地域の両方におけるペットの飼育と動物病院の開発が、皮膚科、心臓血管、内分泌療法用の原薬の少量生産を支えています。抗菌薬の使用管理に関する規制の義務化は、再製剤化の努力とスペクトラムの狭い原薬の開発を促しています。アジアとラテンアメリカを中心とする地域の原薬生産拠点への投資により、サプライチェーンの安定性とコスト効率が向上しています。合成、精製、プロセスバリデーションにおける戦略的アウトソーシングと技術的近代化は、世界中の動物用医薬品原薬製造施設の能力とコンプライアンスをさらに強化しています。

セグメント

サービス（インハウスサービス、受託アウトソーシングサービス）;合成タイプ（化学ベースのAPI合成、生物学的API合成、HPAPI合成）;動物タイプ（生産動物、コンパニオンアニマル）;治療カテゴリー（抗寄生虫治療薬、抗感染症治療薬、非ステロイド性抗炎症薬治療薬、その他の治療カテゴリー）

調査対象企業の例

• Alivira Animal Health Limited
• AMGIS Lifescience Ltd
• Ceva Sante Animale S.A.
• Chempro Pharma Private Limited
• Divi's Laboratories Limited
• Excel Industries Limited
• FIS-Fabbrica Italiana Sintetici S.p.A.
• Grupo Indukern S.L.
• Huvepharma AD
• Jiangsu Lingyun Pharmaceutical Co., Ltd.
• Menadiona S.L.
• Neuland Laboratories Limited
• NGL Fine-Chem Ltd.
• Norbrook Laboratories Limited
• OFICHEM Group B.V.
• Phibro Animal Health Corporation
• Qilu Pharma Spain S.A.
• Sequent Scientific Limited
• SUANFARMA S.A.
• Vetoquinol S.A.
• Vetpharma Animal Health S.L.
• Virbac S.A.
• Zoetis Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market to Reach US$12.5 Billion by 2030

The global market for Veterinary Active Pharmaceutical Ingredients Manufacturing estimated at US$8.7 Billion in the year 2024, is expected to reach US$12.5 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. In House Service, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$9.3 Billion by the end of the analysis period. Growth in the Contract Outsourcing Service segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 10.0% CAGR

The Veterinary Active Pharmaceutical Ingredients Manufacturing market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market - Key Trends & Drivers Summarized

Why Is Veterinary API Manufacturing Central to Animal Health Supply Chains?

Veterinary active pharmaceutical ingredients (APIs) are the core biologically active substances used to formulate medications for animals. These APIs form the basis of drugs used for disease prevention, treatment, and performance enhancement in livestock, companion animals, and aquatic species. Veterinary API manufacturing supports a wide spectrum of products, including antibiotics, anti-parasitics, anti-inflammatories, and vaccines. The manufacturing process involves synthesis, fermentation, purification, and formulation of APIs that meet regulatory quality standards for animal use.

Manufacturing of veterinary APIs must adhere to specific pharmacopoeial guidelines and good manufacturing practices (GMP), with added emphasis on contamination control and species-specific efficacy. As animal health becomes closely tied to food safety, public health, and economic productivity, secure and consistent API supply is essential for the continuity of veterinary healthcare systems. This has heightened the focus on supply chain resilience, particularly for high-volume livestock drugs used in poultry, swine, and bovine segments.

How Are Regulatory Shifts and Global Trade Influencing API Production?

Veterinary API manufacturing is shaped by evolving regulatory frameworks focused on drug residue limits, antimicrobial stewardship, and export quality compliance. Many regions now require traceability and transparent documentation of the origin and composition of veterinary drugs. This has increased scrutiny on API manufacturers and driven demand for production facilities that comply with veterinary GMP standards, such as those issued by the FDA, EMA, and national veterinary authorities.

International trade of veterinary APIs is also affected by harmonization initiatives, such as VICH guidelines and Codex Alimentarius standards. These influence residue monitoring programs and acceptable daily intake limits for veterinary drugs in animal-derived food products. Manufacturers must navigate differing approval pathways for veterinary APIs across regions, often requiring customized production and documentation for each export destination. These compliance requirements are prompting both large and mid-sized API producers to expand certifications, improve audit readiness, and invest in region-specific regulatory expertise.

What Role Do Process Technologies and Outsourcing Models Play in Manufacturing Strategy?

Advancements in synthesis, fermentation, and downstream processing technologies are enabling greater control over purity, yield, and production cost. Manufacturers are increasingly adopting continuous processing and modular production systems to improve throughput and reduce contamination risks. Microbial and enzymatic synthesis methods are being applied to veterinary hormone and vitamin APIs, while complex molecules such as antiparasitic agents require highly controlled chemical synthesis workflows.

Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are playing a larger role in veterinary API supply chains. Many animal health companies outsource API production to dedicated third-party producers who specialize in veterinary-grade materials. This model supports scalability, cost optimization, and regulatory compliance while allowing drug developers to focus on formulation and distribution. As veterinary pharmaceutical pipelines diversify into biologics, CMOs with biologics capabilities are becoming integral partners in active ingredient development.

What Factors Are Supporting Growth in Veterinary API Manufacturing Globally?

Growth in the veterinary active pharmaceutical ingredients manufacturing market is driven by several factors related to rising demand for animal protein, increased companion animal care, and stricter disease management protocols. Expansion of commercial livestock farming and aquaculture is driving volume demand for antiparasitics, antibiotics, and nutritional APIs. Growth in pet ownership and veterinary clinics in both developed and emerging regions is supporting small-batch production of APIs for dermatological, cardiovascular, and endocrine therapies. Regulatory mandates for controlled antimicrobial use are prompting reformulation efforts and development of narrow-spectrum APIs. Investments in regional API production hubs, particularly in Asia and Latin America, are improving supply chain stability and cost efficiency. Strategic outsourcing and technological modernization in synthesis, purification, and process validation are further enhancing the capacity and compliance of veterinary API manufacturing facilities worldwide.

SCOPE OF STUDY:

The report analyzes the Veterinary Active Pharmaceutical Ingredients Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (In House Service, Contract Outsourcing Service); Synthesis Type (Chemical-based API Synthesis, Biological API Synthesis, HPAPI Synthesis); Animal Type (Production Animals, Companion Animals); Therapeutic Category (Antiparasitic Therapeutic, Anti-infectives Therapeutic, NSAIDs Therapeutic, Other Therapeutic Categories)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Alivira Animal Health Limited
• AMGIS Lifescience Ltd
• Ceva Sante Animale S.A.
• Chempro Pharma Private Limited
• Divi's Laboratories Limited
• Excel Industries Limited
• FIS - Fabbrica Italiana Sintetici S.p.A.
• Grupo Indukern S.L.
• Huvepharma AD
• Jiangsu Lingyun Pharmaceutical Co., Ltd.
• Menadiona S.L.
• Neuland Laboratories Limited
• NGL Fine-Chem Ltd.
• Norbrook Laboratories Limited
• OFICHEM Group B.V.
• Phibro Animal Health Corporation
• Qilu Pharma Spain S.A.
• Sequent Scientific Limited
• SUANFARMA S.A.
• Vetoquinol S.A.
• Vetpharma Animal Health S.L.
• Virbac S.A.
• Zoetis Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Veterinary Active Pharmaceutical Ingredients Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Demand for Livestock Health and Productivity Enhances Investment in Veterinary API Manufacturing Capacity
  • Expansion of Companion Animal Healthcare Markets Strengthens the Business Case for High-Purity Veterinary API Production
  • Growing Incidence of Zoonotic Diseases Spurs Innovation in Veterinary Antibiotics and Antiviral API Manufacturing
  • Stringent Regulatory Compliance in Animal Drug Approvals Drives Adoption of GMP-Certified Veterinary API Facilities
  • Surge in Global Meat and Dairy Consumption Fuels Demand for Anti-Infective and Growth-Promoting Veterinary APIs
  • Increasing R&D in Targeted Parasiticides and Antimicrobials Creates Opportunities for Specialized Veterinary API Manufacturers
  • Shift Toward Preventive Animal Health and Immunotherapy Supports Expansion of Veterinary API Pipelines
  • Rising Demand for Customized and Species-Specific Formulations Promotes Diversification of Veterinary API Product Lines
  • Growing Adoption of Biologics and Peptide-Based APIs in Veterinary Medicine Spurs Biotech-Oriented Manufacturing Investments
  • Globalization of Veterinary Drug Supply Chains Strengthens Outsourcing Trends in API Production
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Veterinary Active Pharmaceutical Ingredients Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for In House Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for In House Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for In House Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Contract Outsourcing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Contract Outsourcing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Contract Outsourcing Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for NSAIDs Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for NSAIDs Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for NSAIDs Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapeutic Categories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Therapeutic Categories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Therapeutic Categories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Antiparasitic Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Antiparasitic Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Antiparasitic Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Anti-infectives Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Anti-infectives Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Anti-infectives Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Chemical-based API Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Chemical-based API Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Chemical-based API Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Biological API Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Biological API Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Biological API Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for HPAPI Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for HPAPI Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for HPAPI Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Production Animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Production Animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Production Animals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Companion Animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Companion Animals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Companion Animals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• JAPAN
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• CHINA
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: China 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: China 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: China 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: China 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• EUROPE
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• FRANCE
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: France 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: France 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: France 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: France 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• GERMANY
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Germany 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Germany 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Germany 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Germany 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Italy 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Italy 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Italy 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Italy 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 137: UK Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: UK 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: UK 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: UK 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: UK 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Spain 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Spain 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Spain 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Spain 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Russia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Russia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Russia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Russia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Australia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Australia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Australia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Australia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• INDIA
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 212: India Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: India 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 215: India Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: India 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: India 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: India 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: South Korea 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: South Korea 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: South Korea 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: South Korea 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Argentina 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Argentina 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Argentina 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Argentina 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Brazil 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Brazil 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Brazil 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Brazil 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Mexico 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Mexico 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Mexico 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Mexico 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Iran 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Iran 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Iran 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Iran 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Israel 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Israel 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Israel 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Israel 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: UAE 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: UAE 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: UAE 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: UAE 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030
• AFRICA
  • Veterinary Active Pharmaceutical Ingredients Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - In House Service and Contract Outsourcing Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: Africa 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Service - Percentage Breakdown of Value Sales for In House Service and Contract Outsourcing Service for the Years 2014, 2025 & 2030
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Africa 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Therapeutic Category - Percentage Breakdown of Value Sales for NSAIDs Therapeutic, Other Therapeutic Categories, Antiparasitic Therapeutic and Anti-infectives Therapeutic for the Years 2014, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Africa 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API Synthesis, Biological API Synthesis and HPAPI Synthesis for the Years 2014, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Production Animals and Companion Animals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Africa 16-Year Perspective for Veterinary Active Pharmaceutical Ingredients Manufacturing by Animal Type - Percentage Breakdown of Value Sales for Production Animals and Companion Animals for the Years 2014, 2025 & 2030

IV. COMPETITION